The aim of this analysis was to explore the diversity of reduced intensity conditioning (RIC) in paediatric allo-SCT in daily practice across Europe. Data from the European Group for Blood and Marrow Transplantation (EBMT) Promise database from 1994 to 2008 were supplemented by a survey of EBMT centres performing paediatric allo-SCT on the current policy asking for the underlying diseases and for the drug combinations. Records from 161 centres from 30 countries were analysed and 139 various RIC regimens were reported. More centres applied RIC for malignant rather than for non-malignant diseases. In general, fludarabine (FLU)-based regimens predominated except for BU-based regimens in myeloid malignancies and haemoglobinopathies. Treosulfan (TREO) was mainly applied for unspecified malignant diseases and for haemophagocytic diseases. FLU-based regimens revealed the greatest number of different combinations. Correlating the number of regimens with the number of treating centres revealed the lowest variety in FLU and the highest variety in TBI and TREO. FLU/melphalane and FLU/CY were the most frequent combinations. This extreme heterogeneity in RIC may influence both the efficacy and the safety of the procedures, which requires further investigation. Optimization and standardization of RIC is the final goal to provide a platform for future prospective studies.
INTRODUCTION
Reduced intensity conditioning (RIC) regimens represent a recognized and consolidated approach for allo-SCT for many malignant and non-malignant disorders in adults and children. RIC aims to decrease short-and long-term complications of myeloablative conditioning (MAC) while promoting adequate engraftment with stable donor-derived haematopoiesis. 1 RIC is based on immunosuppression, usually achieved by the use of purine analogues like fludarabine (FLU) in combination with reduced doses of alkylating agents or low-dose irradiation (TBI or TLI).
In malignant diseases, RIC enables allo-SCT in patients with high-risk disease, second transplant and/or coexisting comorbidities that preclude MAC. [2] [3] [4] [5] [6] [7] [8] For non-malignant diseases, paediatric RIC-allo-SCT is well established in patients with SAA and Fanconi's anaemia, in primary immunodeficiences and some metabolic disorders. [9] [10] [11] Regarding the definitions of RIC and non-MAC several workshops and reports have been convened on this issue: first the 'Champlin criteria' were defined followed by further attempts under the sub-auspices of the European Group for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Taken together, the majority of published definitions and recommendations consider regimens with FLU ⩽ 180 mg/m 2 , busulfan ⩽ 9 mg/kg, melphalan ⩽ 140 mg/m 2 , thiotepa ⩽ 10 mg/m 2 , CY ⩽ 60 mg/kg and TBI less than 5 Gy as a single fraction or 8 Gy in fractionated doses as RIC. [12] [13] [14] [15] [16] [17] The addition of ATG or other mono-or polyclonal antilymphocyte antibodies or purine analogues does not change the intensity of RIC. 18 At the beginning of this decade more than a quarter of conditioning therapies for allo-SCT consisted of RIC regimens but variations among European countries have been observed, even within precisely defined disease subgroups. 19 The reported outcomes of paediatric RIC allo-SCT vary markedly and may to a certain extent reflect the differences in the practices of RIC. 20 This might represent a problem for interpreting published results.
To better understand the current practice of allo-SCT teams treating children with RIC, the EBMT-Paediatric diseases and the Complications and Quality of Life-Working Party performed a retrospective analysis of data from the EBMT database and this was supplemented by a survey of centres on the current policy asking for the underlying diseases and for the most common drug combinations. These analysis data should be the basis for further harmonization and conditioning recommendations with a planned prospective study about similar patient cohorts and their outcome and toxicity data.
Study design
We retrospectively analysed data from the EBMT Promise database from 1994 until 2008 on underlying diseases, indications and drug combinations in children who received an RIC-allo-SCT. In addition, a questionnaire about current practice was sent out to all EBMT centres, which performed allo-SCT for patients under the age of 18 years since 2000 (203 centres).
MATERIALS AND METHODS
The EBMT Promise database was searched from 1994 until 2008 and patients between 0 and 18 years of age indicated as having received an RIC-allo-SCT for malignant or non-malignant diseases both from related and from unrelated donors. First and/or subsequent transplants were included. Exclusion criteria were missing entries on regimen drugs. A supplementary survey of 203 EBMT centres performing paediatric allo-SCT was carried out between 23/07/2007 and 01/11/2009. The questionnaire asked for the centre's current indications for RIC and the details of the RIC regimens used. Rather than classifying 'reduced intensity' centrally according to the EBMT consensus guidelines, centres were asked to define and specify their own RIC protocols and answers from 29 EBMT centres could be included. Duplicates were removed and patients who received obviously non-RIC protocols were analysed separately.
Our analyses were divided into three major parts: (i) disease-specific (number of centres), (ii) regimen-specific (number of regimens; one regimen combination counts as one regimen but different dosage variations were not considered; a sub-analysis of reasons why RIC has been chosen was included) and (iii) centre-specific evaluation (the type of centre (paediatric only vs adult and paediatric) and the influence of the size of a centre). Furthermore national details were analysed. For clarification, we have categorized the diseases and the RIC regimens as shown in Table 1 . (Of note BU-based regimens were counted as BU even with the addition of FLU.) We defined one regimen as one specific combination of drugs with or without radiotherapy (RT) and antibody therapy (AB) regardless of the dosage.
Statistical methods
The reports and the registry data were analysed at the EBMT-PD-WP Data office in Paris, France. To extract the data from the EBMT registry (Promise) the software SPSS (IBM SPSS Statistics 19, Stanford, CA, USA) was used. The software R (version 2.13.0, R Development Core Team, 2010, Vienna, Austria) was used for analysis. Pearson coefficient correlation was utilized to find a correlation between at least two continuous variables. Data were analysed in R and exported to Excel (Microsoft Office Excel 2011, Seattle, WA, USA).
RESULTS
We evaluated data from 161 centres from 30 countries with a good geographical coverage. In total, 106 were paediatric centres, 44 were adult centres performing paediatric allo-SCT and 11 were not specified BMT units. In all, 42 centres had to be excluded due to incomplete data. Data were obtained from 1081 registry entries and from 29 completed questionnaires.
Use of RIC in different disease categories In all, 68/161 centres (42.2%) used RIC regimens to treat both malignant and non-malignant diseases, whereas 67/161 centres (41.6%) used RIC only for malignant diseases and 26/161 centres (16.1%) only for non-malignant diseases. More centres applied RIC for malignant than for non-malignant diseases (135 vs 94). Further details about the numbers of centres that used RIC for the different underlying disease categories are shown in Figure 1 .
The percentage of centres applying the diverse RIC regimens in different disease groups is displayed in Table 2 .
In malignant diseases, FLU-based regimens were predominantly used in all disease categories. The percentage of centres that used the different RIC regimens in malignant diseases is shown in Figure 2 .
Regarding the non-malignant diseases the percentage of centres that applied the diverse RIC categories is shown in Figure 3 . FLU-based regimens were predominantly used also in nonmalignant diseases except in haemoglobinopathies (HB-PATH), for which BU-based conditioning was mainly applied.
Details of RIC regimens
Within the different RIC regimens, there was a wide variety of drug combinations conveyed. A total of 139 different regimens were reported, with 103 regimens for malignant diseases and 81 for non-malignant diseases. 71  67  67  79  73  25  71  92  75%  BU  32  51  3  27  43  46  17  26  0  TREO  7  9  3  10  13  13  21  2  0  ALKYL  15  10  15  30  7 EBMT-Survey on paediatric RIC
The number of regimens per RIC category is shown in Figure 4 . To better understand the heterogeneity, we also correlated the number of the regimens within each category with the number of centres that used those and depicted the quotient as ratio (R) also shown in Figure 4 .
The largest number of different regimens was seen in the FLUbased group followed by the BU-based group. The ratio (R) depicts the variety of the miscellaneous RIC regimens and showed the highest variety in TBI, followed by Treosulfan (TREO). When we next correlated the ratio with the categorized disease groups we found a slightly higher variety in non-malignant than in malignant diseases (0.86 vs 0.76). The highest variety was observed in myeloid leukaemias (ML) (0.84) for the malignant disease group and in HB-PATH (1.08) for the non-malignant diseases.
Considering the components within the RIC categories the regimen used by the largest number of centres was FLU (without BU) plus melphalan or plus CY (± AB). BU was combined mostly with FLU or CY and TREO with FLU ( ± AB). VP16 was applied typically with melphalan plus BCNU plus ARA-C.
Reason for choosing RIC For this subanalysis, 602/1081 registry entries could be evaluated and the relation of malignant to non-malignant diseases was nearly equal. The following indications were reported: 'Protocol driven' in malignant vs non-malignant diseases was 40 vs 64%, 'Comorbidities'' 27 vs 18%, 'second and subsequent allo-SCT'' 29 vs 10%, 'Age' 1 vs 5% and unspecified reasons 3% in both groups. For further information how RIC was prioritized over MAC we analysed the registry data of those 17 centres that applied RIC most.
Between 1994 and 2001 the total denominator (mean number) of allo-SCT was 167 (range 8-317) and RIC was used in mean 3.2% (range 0.5-8%) of them. In contrast, the percentage of RIC increased to mean 13.5% (range 4. Centre-specific analysis Within the 161 centres included in the analysis, 106 (66%) were paediatric centres and 44 (27%) combined adult and paediatric centres and 11 unspecified BMT units. There was a tendency to use more first RIC-allo-SCT in combined than in paediatric only centres.
When looking at applied regimen categories there were no significant differences. Slightly more combined centres used FLU (92 vs 82%), BU (59 vs 42%), RT (5 vs 2%) and TBI (11 vs 9%). A higher percentage of paediatric centres compared with combined centres used TREO (15 vs 9%). The other regimens showed a similar distribution and variety of drug combinations. The correlation between the number of transplants performed and the number of regimens is strong (r = 0.50840.5), which means that centres that performed fewer transplants per year used less different RIC regimens (data not shown). National details In all, 161 centres from 30 countries reported details and the country with the highest number of contributing centres is France (24 centres), followed by Italy (20 centres), UK (19 centres), Germany (16 centres) and Poland (9 centres). When looking at the country-specific analysis a higher number of different categories were applied in those countries with more contributing centres. Approximately one-quarter of countries, representing the majority (56%) of centres, used 6-8 different regimens; a second quarter of countries, representing 31% of the centres, applied 4-5 different RIC categories. In all, 1-3 diverse regimens were only reported by 13% of the centres, which were distributed in about half of the participating countries.
DISCUSSION
This analysis of RIC in paediatric patients with both malignant and non-malignant diseases obtained data not only from the EBMT registry but also from a survey among EBMT centres. The study aimed to gain information on the underlying diseases, indications and drug combinations of RIC and the centres' individual preference for the different approaches over a broad period of time. It was not intended to investigate efficacy and outcome of the applied conditioning in different diseases. The purpose was to create a platform for standardization and for planning prospective studies about outcome and toxicity data within the EBMT community.
The key finding of our survey was that as many as 139 various RIC regimens were applied by 161 centres. Of note, we did not include details on the different types and doses of antibody preparations, as well as on the various doses of RT below 6 Gy. It is obvious that the addition of these items would have resulted in even greater diversity. At a first look, this is a disappointing result, but going into details, it reflects the daily practice of paediatricians, facing an enormous variety of transplant indications with a strong request for a patient adapted strategy. The same is true for the huge variety of immunodeficiency syndromes where a centre might expect one patient in each type of PID in a decade. Thus, the large number of 139 applied RIC regimens may also reflect the difficulty of sharing appropriate information or performing studies on children with orphan diseases.
More centres applied RIC for malignant rather than for nonmalignant underlying diseases, which reflects the distribution of those disease groups as 2/3 of paediatric patients are transplanted for leukaemia and other malignancies. The most frequent malignant indication was ML, perhaps because paediatric patients with myeloid leukaemia are heavily pre-treated with pre-existing organ dysfunction and/or severe infection which preclude conventional conditioning. 21 Another reason may be that recently, it has been demonstrated that RIC may be comparable to MAC in MDS patients. 11, 22 For the non-malignant diseases, the most common indication was PID. Here it has been shown over several decades that in certain disease categories, stable donor engraftment could be obtained with no or little chemotherapy and MAC for disease eradication is not required. 9, 23, 24 Reduced toxicity is of particular interest in this disease category with a significant proportion of very young children under the age of 1 year. 9, 25 A further advantage may be in reducing some of the long-term sequelae of MAC in these children. 9, 10 In general FLU-based regimens, mainly in combination with MEL or CY, were the most commonly used. FLU is a highly T-cell toxic drug with a relatively low organ toxicity profile. 26 Considering the subgroups of malignant diseases, BU-based regimens were only slightly less applied compared with FLU for treating ML, whereas for lymphoid leukaemias (LL) much less BU was applied, which may be explained by the fact that TBI-based regimens were preferred to BU-based regimens. HB-PATH that are associated with the high risk of rejection 27 predominantly were conditioned with lower doses of BU. TREO was mainly applied for UNSPEC.MAL and haemophagocytic disorders (HPD) where achievement of full donor chimaerism with limited toxicity is crucial. 25 Analysing the various drug combinations within each regimen group, FLU-based regimens revealed the greatest number of different combinations, which may be due to the fact that this was by far the most commonly used regimen category. However, when correlating the number of regimens used with the number of centres we perceived the lowest diversity for FLU. The highest variety was observed in TBI (mainly applied in ML) and TREO (mainly applied for UNSPEC.MAL and HPD). Of note, for LL and ML patients there were 14 different regimens reported containing TBI of more than 7 Gy (50% in combination with FLU) which by definition, are not considered to be RIC according to the EBMT definition. Unfortunately, we did not get details about TBI fractions. For TREO, the fact that this is a relatively new drug might give the reason for the observed diversity. In general, there was a higher variety of drug combinations in non-malignant diseases perhaps explained by the greater assortment of underlying conditions. Peak diversity was observed for ML (0.84) in the malignant and for HB-PATH (1.08) in the non-malignant diseases. This enormous variety of the diverse combinations of agents was surprising but may reflect the fact that no widely accepted guidelines have been published, and no large multicenter paediatric RIC studies have been launched.
Regarding the reasons for choosing RIC the decision was predominantly made on the basis of protocols particularly for the non-malignant diseases. Second and subsequent allo-SCT was more often reported as an indication in malignant diseases, which may be seen in the context of relapsed underlying diseases. Not surprisingly age was more often reported as a rationale in the nonmalignant diseases. Notably data obtained from the registry cover a long time period (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) and at the beginning of this time period the numbers of RIC-allo-SCT for malignant diseases were considerably higher than for non-malignant diseases. In addition, most RIC consensus papers were published in the latter part of this time period. For getting an impression how RIC was prioritized over MAC data of the 17 centres that used RIC most were analysed. The total denominator of allo-SCT and the percentage of RIC are displayed as mean numbers. Between 1994 and 2001 3.2% of 167 allo-SCT were reported as RIC and the increasing application can be perceived as 13.5% of 180 allo-SCT were specified as RIC between 2002 and 2008.
One of the limitations is that this activity survey does not provide a complete overview on the current practice of EBMT centres and that the distribution of paediatric and combined centres is unbalanced with more paediatric centres included. However, data from a large number of active centres were analysed and the geographical distribution of the participating centres was wide. Despite inadequate survey responses, incomplete data set availability in the EBMT database and limitations of a retrospective registry data analysis of a heterogenous patient population the major message is that there is a tremendous variability in RIC regimens utilized at various centres within the EBMT community.
As much as we want to standardize and categorize our conditioning regimens, it may well be that in the future the strict definitions regarding the intensity of a given conditioning regimen will be obsolete, and we will have to consider a more complex definition that will take into account factors related to the patient, the donor, the disease and the conditioning regimen. For instance with BU, drug exposure defined by pharmacokinetics analysis rather than dosing on weight or BSA better defines transplant outcomes and pharmacokinetics may be equally important in defining long-term sequelae. 28 The impact of dose intensity may differ from disease to disease, especially regarding the effect on chimaerism and anti-neoplastic properties 15, 29 and will be further complicated by the use of a variety of serotherapies in various dosages. Therefore, prospective studies not only have to consider different dosages within the same drug combinations and uniform GVHD prophylaxis, but also should be disease specific, to gain further insight into long-term outcome and late effects.
In conclusion, the present survey demonstrates significant differences and tremendous variability in the use of RIC regimens in paediatric allo-SCT. As of today there are no data to favour one protocol over the other. Additionally, one of the major potential advantages of RIC for the paediatric patient population, besides reducing short term toxicity, may be the potential for causing fewer long-term sequelae including fertility preservation. There is no way one can draw any conclusions on the superiority of RIC over MAC regimens, unless a smaller number of specific RIC regimens are agreed upon and used by a large number of centres, allowing collection of detailed outcome data.
